Pfizer’s recent determination to pay $43bn for antibody-drug conjugate (ADC) pioneer Seagen, the largest pharmaceutical deal since AbbVie’s $63bn takeover of Allergan three years ago, stems in part from the remote chance that a biosimilar sponsor would ever be motivated or indeed able to replicate the groundbreaking medicines.
This is according to Pfizer’s CEO Albert Bourla, who spearheaded efforts to turn rumors into reality earlier this week with Pfizer’s all-cash agreement for Seagen, including $31bn of fresh long-term debt
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?